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Abstract
This paper examines the controversial topic of choosing our
children’s genes through human germ-line manipulation otherwise
known as Inheritable Genetic Modification (IGM) with current
Assisted Reproductive Technologies (ARTs) and future Reproductive
Genetic Biotechnologies (RGBs) such as genetic engineering. The
purpose of the paper is to examine these potentially revolutionary
biotechnologies and the emerging social, and bioethical perspectives
advanced by both proponents and opponents—in the context of the
legal and regulatory policies impacting ARTs and RGBs. Lastly, the
paper recommends new public policy and regulatory frameworks to
support future research and development of RGBs by providing
legislative guidance to policymakers to ensure responsible oversight.
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INTRODUCTION
As research and development continues to advance humankind’s
understanding of the human genome, our biology, and ultimately our
biological potential as a species, new biotechnologies will emerge that
may soon enable parents to choose the future genetics and traits of
their children. Normal sexual reproduction supports genetic variation
in gametes, expressed through changes in alleles located at specific
locations on the chromosome that pass dominant traits from parent to
offspring.1 This process of Mendelian inheritance is expressed in two
laws: the Law of Segregation and the Law of Independent
Assortment, whereby each of the 46 chromosomes segregates during
meiosis, each with a 50 percent chance of segregating to a particular
cell.2 These fundamental principles of classical genetics frame
Humankind’s pragmatic abstraction of evolution—that genetic
determinism produces children born with distinct biological
advantages or desired phenotypic traits. Proponents of genetic
engineering technologies argue that if pursued, such advancements
could one day enable parents to choose the genes of their children,
and if presented with the opportunity, humankind should seize control
of its own destiny.3 Humanity, according to such proponents, should
transcend the draconian and arguably prehistoric practice of random
genetic variation through sexual reproduction and natural selection to
begin a new era of human self-design. This ideology is predicated on
the belief that Humankind is running twenty-first century software
(our knowledge) on Stone Age hardware (our bodies) that have not
changed in the last 50,000 years.4
However, opponents of genetic engineering technologies argue
that biologically altering humankind is such a radical choice, that its
consequences could have the potential to destroy humanity itself,
leaving behind an unrecognizable species, far removed from
morality.5 This ideology advanced by opponents emphasizes several

1. See CECIE STARR ET AL., BIOLOGY: THE UNITY AND DIVERSITY OF LIFE 154-200
(12th ed. 2009).
2. See id. at 156-57, 173-74.
3. See GREGORY STOCK, REDESIGNING HUMANS: CHOOSING OUR GENES, CHANGING
OUR FUTURE 2 (2003).
4. See SURVIVING PROGRESS (Cinemaginaire and Big Picture Media Corporation, in
Coproduction with the National Film Board of Canada 2012).
5. See PRESIDENT’S COUNCIL ON BIOETHICS (U.S.), REPRODUCTION AND
RESPONSIBILITY: THE REGULATION OF NEW BIOTECHNOLOGIES xii (2004) [hereinafter
REPRODUCTION AND RESPONSIBILITY].
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issues including: the safety risks imposed,6 feasibility of the science
and technology,7 and precautionary principle.8 Opponents’ precaution
is predicated on the principle that some technologies are so inherently
dangerous to humankind; they should be considered a Pandora’s Box
that should never be pursued, regardless of the potential benefits.9
A. Thesis
First, this paper will attempt to elucidate both sides of the
controversial debate of enabling parents, by means of current Assisted
Reproductive Technologies (ARTs) and future Reproductive Genetic
Biotechnologies (RGBs), to choose the genes or genetic traits of their
children. The paper will examine current genetic engineering and
future genetic modification technologies by evaluating their scientific
feasibility, applicability, and development towards enabling parents to
choose the genetics of their children. Technologies such as: Gene
Therapy, Germline engineering, and Human Artificial Chromosomes
(HACs) will be discussed. In addition, the advancement and impact
of the Human Genome Project (HGP) will be examined in the context
of its impact on the progression of past, present, and future genetic
modification technologies.10
Second, the social and bioethical implications of genetic
modification will be examined in the context of the complex and
diverse range of ideologies and perspectives from both prominent
proponents and opponents of genetic modification.
Prolific
proponents—such as Gregory Stock, Julian Savulescu, Lee Silver,
and Ray Kurzweil—argue genetic engineering is a promising and
desirable technology that could potentially revolutionize and
transform humankind by improving our body and our minds.11
Visceral opponents—such as Leon Kass, Francis Fukuyama, and Bill
McKibben—argue inevitable genetic engineering technologies would
radically redefine the definition of humankind by manipulating
inheritable genetic and epigenetic traits such as: intelligence, athletic

6.
7.

See id. at xi.
See FRANCIS FUKUYAMA, OUR POSTHUMAN FUTURE: CONSEQUENCES OF THE
BIOTECHNOLOGY REVOLUTION 82 (2002).
8. See Bill Joy, Why the Future Doesn’t Need Us, WIRED (Apr. 2000),
http://www.wired.com/wired/archive/8.04/joy_pr.html.
9. See id.
10. STOCK, supra note 3, at 42.
11. See generally STOCK, supra note 3; RAY KURZWEIL, THE SINGULARITY IS NEAR:
WHEN HUMANS TRANSCEND BIOLOGY (2005); JULIAN SAVULESCU ET AL., ENHANCING HUMAN
CAPACITIES (2011); LEE M. SILVER, REMAKING EDEN (1998).
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ability, and longevity.12 These opponents express deep concern of its
potential destructive impact on the social, ethical, and philosophical
framework of society.13
Finally, the paper describes the current regulatory frameworks of
governmental and nongovernmental agencies that exercise limited
regulatory authority over genetic engineering technologies. In
addition, the paper examines the possible future regulations of genetic
engineering technologies. Lastly, the paper attempts to balance the
costs and benefits of the relevant technologies against the social and
bioethical implications in order to recommend guidelines for
legislators to consider when seeking practical and prudent public
policy solutions.
I.

UNDERSTANDING GENETIC ENGINEERING TECHNOLOGIES
A. Assisted Reproductive Technologies (ARTs)

ARTs include a wide range of medical treatments and
procedures involving the manipulation of human eggs and sperm
inside and outside the human body.14 ARTs such as, In Vitro
Fertilization (IVF), and Pre-implantation Genetic Diagnosis (PGD)
have been gateway technologies to all the advanced reproductive
technologies now emerging, in addition to prospective technologies
such as germline engineering.
Moreover, as humankind’s
understanding of our genomic information and genes that correspond
to disease linked genetic markers increase as a result of the Human
Genome Project (HGP), the intersection of IVF, PGD, and genomics
may potentially form the requisite catalyst needed to enable parents to
choose the positive genetic traits and characteristics of their
offspring.15

12. See generally PRESIDENT’S COUNCIL ON BIOETHICS (U.S.), BEYOND THERAPY:
BIOTECHNOLOGY AND THE PURSUIT OF HAPPINESS (2003) [hereinafter BEYOND THERAPY];
FUKUYAMA, supra note 7; BILL MCKIBBEN, ENOUGH: STAYING HUMAN IN AN ENGINEERED
AGE xi-xiii (2003).
13. Id.
14. See 42 U.S.C. § 263a-7(1) (2006) (“The term “assisted reproductive technology”
means all treatments or procedures which include the handling of human oocytes or embryos,
including in vitro fertilization, gamete intrafallopian transfer, zygote intrafallopian transfer, and
such other specific technologies.”).
15. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 102; see also Susannah
Baruch, Preimplantation Genetic Diagnosis and Parental Preferences: Beyond Deadly Disease,
8 HOUS. J. HEALTH L. & POL’Y 245, 251 (2008).
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B. The Human Genome Project (HGP)
Until the HGP was proposed, scientists had to work with small
portions of genetic material, usually consisting of only a few genes as
they struggled to understand how genetic mutations caused diseases.16
Although the HGP offers great promise for humankind to gain control
of our evolution, this is far from the minds of scientists working
toward understanding the genome. Scientists are more focused on
disease prevention: “identifying disease-related genes, developing
diagnostic tests, finding effective new drugs, understanding cancer
and other diseases.”17 The ambitious goals of the HGP included two
revolutionary outcomes: (1) “the genome was mapped at a relatively
high level. This means that researchers systematically determined the
linear order of genes on each chromosome using applied genomics to
identify and localize genes in a process known as transcript
mapping,”18 and (2) “[t]he Messenger RNA transcripts from
expressed genes are converted to complementary DNAs (cDNAs),
which are then sequenced and mapped to sites on particular
chromosomes.”19 This revolutionary work in genomic analysis and
gene mapping was completed with the announcement in 2003 of the
completion of sequencing the 3-billion-base pairs of Human DNA.20
The project reinvigorated the aspirations of those seeking to improve
the human race through genetic engineering and reproductive
technologies. With the completion of sequencing the human genome,
researchers are more able to quickly and easily diagnose genetic
diseases and identify life-threatening prenatal genetic abnormalities.21
Since its completion in 2003, remarkable innovations in genetic
mapping and computational power have increased the speed,
accuracy, and efficiency of sequencing the human genome with recent
techniques demonstrating rapid and non-invasive Whole-Genome
Sequencing (WGS) of a human fetus for genetic diagnosis.22 Gregory

16. See John Robertson, Procreative Liberty in the Era of Genomics, 29 AM. J.L. & MED.
439-40 (2003).
17. STOCK, supra note 3, at 42.
18. ROBERT P. MERGES ET AL., INTELLECTUAL PROPERTY IN THE NEW TECHNOLOGICAL
AGE 568 (2010).
19. Id.
20. See U.S. Dep’t of Energy, About the Human Genome Project, HUMAN GENOME
PROJECT
INFORMATION
ARCHIVE
1990–2003,
http://web.ornl.gov/sci/techresources/Human_Genome/project/index.shtml.
21. See Maxwell J. Mehlman, The Law of Above Average: Leveling the New Genetic
Enhancement Playing Field, 85 IOWA L. REV. 517, 521-22 (2000).
22. See Jacob O. Kitzman et al., Non-Invasive Whole Genome Sequencing of a Human
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Stock, a proponent of genetic engineering technologies and futurist
recognizes the HGP as an “extraordinary accomplishment, [where]
humanity took a giant step toward unraveling its biology and
manipulating it in profound ways.”23 Stock envisions that “[t]he
immediate consequence of uncovering the more than thirty thousand
human genes and their variants will be better identification of our
genetic susceptibilities to various diseases and better treatments for
them.”24 However, Stock also anticipates that with the completion of
the HGP, and a better understanding of our gene related traits and
characteristics, future RGBs will be developed to purposely
manipulate our genes with somatic cell therapy.25 In contrast, others
have expressed concerns about the completion of the HGP, and the
consequences of the future use of genomic sequencing in
reproduction, because it raises important social and ethical questions
about people deciding to procreate based on their genetic makeup, or
that of their embryo or fetuses.26
1. Genome Sequencing
Since the completion of the HGP, several companies have
capitalized on the opportunity to provide consumers with a
confidential, fast, and relatively inexpensive detailed analysis of their
genetic information. These services genotype an individual’s genetic
information and compare it against the probabilities that other
individuals who share the same specific genetic traits or genomic
markers may have previously experienced medical complications.27

Fetus, 4 SCI. TRANSLATIONAL MED. 1 (June 6, 2012); see also Ying-Ming Zheng et al., Whole
Genome Amplification in Preimplantation Genetic Diagnosis, 12 J. ZHEJIANG U.-SCI. B
(BIOMEDICINE & BIOTECHNOLOGY) 1 (2011); cf. Greer Donley et al., Prenatal Whole Genome
Sequencing: Just Because We Can, Should We?, HASTINGS CENTER REP. July-Aug. 2012, 28, 42
(raising important ethical concerns surrounding the application of pre-natal WGS for trait
selection). Next-Generation Screening (NGS) is poised to transform IVF and PGD by enabling
whole genome sequencing of an embryo prior to implantation—thereby enabling parents to
accept or reject an otherwise healthy embryo based on its pre-disposition of developing specific
diseases later in life.
23. STOCK, supra note 3, at 41.
24. Id.; but cf. International Human Genome Sequencing Consortium, Finishing the
Euchromatic Sequence of the Human Genome, 431 NATURE 931, 945 (2004) (stating that in the
initial analysis of the draft sequence, scientists estimated approximately 30,000 human protein
coding genes, which was later discovered to be in the range of 20,000-25,000).
25. See STOCK, supra note 3, at 42.
26. See Robertson, supra note 16, at 440-41.
27. See MIKE MACPHERSON ET AL., ESTIMATING GENOTYPE-SPECIﬁC INCIDENCE FOR
ONE OR SEVERAL LOCI (2007), available at https://23andme.https.internapcdn.net/res/pdf/HICSXIYiYqXreldAxO5yA_23-01_Estimating_Genotype_Specific_Incidence.pdf.
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In addition, an individual’s “genotype-speciﬁc risk” is calculated
based on the probabilities those other individuals who share similar
genetic markers have the propensity to develop, or have developed,
diseases such as diabetes expressed through different clinical research
studies.28
These new genetic genotyping services essentially
formulate their analysis based upon two layers of abstraction;
probabilities on top of probabilities. However inherently abstract
these probabilities may seem at first glance, these testing services are
continuously refining their formulations, which have been found to be
surprisingly accurate for not sequencing an individual’s complete
genome. These direct-to-consumer genome-testing services only
examine an individual’s exome, or the 1% of an individual’s genome
variants and phenotypes most likely to contain information relating to
specific markers for genetic traits or diseases.29 Although these
services are still developing as a result of the completion of the HGP,
the speed and price required to sequence an individual’s genome is
falling rapidly, and in the foreseeable future complete genome
sequencing, (not just the exome) may become as routine as a blood
test in facilitating genetic modification.30
2. Genomic Therapy and Enhancement
As genomic sequencing becomes more ubiquitous, and public
perception becomes more aware of genetic deficiencies or undesirable
traits of an individual’s genome, public attitudes towards funding
genetic modification research may change. Proponents of genetic
engineering argue the distinction between “therapy” and
“enhancement” may one-day ultimately merge as a result of the
HGP’s transformation of ubiquitous whole genome screening.31 As a
result, public attitudes may shift the public debate of “therapy”
towards support of genetic engineering technologies that could cure
an individual’s potential disposition towards genetic mutations or
epigenetic cancer causing abnormalities in their genome. Proponents
would likely agree such a shift in societal attitudes will come as more
and more individuals have their genome analyzed, and learn that they
may be more likely to develop genetic complications such as:
coronary heart disease, atrial fibrillation, or even debilitating

28. See id.
29. See Adam Kiezun et al., Exome Sequencing and the Genetic Basis of Complex Traits,
44 NATURE GENETICS 623 (2012).
30. See STOCK, supra note 3, at 46.
31. Cf. id.

KELLY

2014]

4/2/2014 11:02 PM

CHOOSING THE GENETICS OF OUR CHILDREN

311

conditions such as diabetes, Alzheimer’s or Parkinson’s disease.32
Such a dramatic shift in genetic knowledge may shift public
perception to redefine therapy to include “preventable therapies,”
which would support RGBs.
On the other hand, since the completion of the HGP, opponents
of genetic research take a precautionary approach towards the
discussion of the HGP’s role in genetic engineering because it may
lead to enhancement that goes beyond correcting predisposition to
disease.33 Proponents argue in support of going beyond therapy for
enhancement, because if such improvement of human performance
becomes feasible it could begin a “golden age” for humankind’s
quality of life.34 It is no surprise then, that the sensationalized term
“designer babies”35 has gained recent attention in the media in respect
to this “golden age” of genomic research with coming prospects such
as: “children born with improved genetic endowments, the result
either of careful screening and selecting of embryos carrying
desirable genes, or of directed genetic change (‘genetic engineering’)
in gametes or embryos.”36 Opponents understand “directed genetic
change” or genetic engineering to go beyond what random
reproductive chance has provided, by improving embryos directly by
introducing better genes.37 Futurists such as Stock, acknowledge that
“[t]he media has hyped many recent gene discoveries, but there is no
question that our genes do shape our predisposition and
vulnerabilities. The complexity of most of these influences remains
to be determined, but a few are surprisingly simple.”38 However,
proponents of genetic engineering contend that these futuristic claims
of “designer babies” may not be as sensationalized as they may first
appear. Genetic engineering technologies such as gene transfer,
germline engineering, and Human Artificial Chromosomes (HACs)—
in conjunction with current ARTs—have already shown success with

32. See Robertson, supra note 16, at 461; see also MARK S. FRANKEL & AUDREY R.
CHAPMAN, HUMAN INHERITABLE GENETIC MODIFICATIONS (2000), available at
http://srhrl.aaas.org/projects/human_enhance/reports/germline.pdf.
33. See BEYOND THERAPY, supra note 12, at 4.
34. NATIONAL SCIENCE FOUNDATION, CONVERGING TECHNOLOGIES FOR IMPROVING
HUMAN PERFORMANCE 6 (2002).
35. See Bonnie Steinbock, Designer Babies: Choosing Our Children’s Genes, 372 THE
LANCET 1294, 1294 (2008).
36. BEYOND THERAPY, supra note 12, at 29.
37. See id. at 31.
38. STOCK, supra note 3, at 43.
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directed genetic change in non-human animal embryos in primates.39
These experiments include revolutionary gene-editing techniques
called Crispr and intracytoplasmic sperm injection (ICSI) to produce
genetically modified non-human primates for research, which resulted
in the birth of a healthy rhesus monkey male, named “George.”40
C. Genetic Modification Technologies
Genomic genotyping and the development of ARTs currently
being used to treat genetic illnesses could eventually be applied to
identify and enhance a person’s non-disease genetic characteristics or
traits. This broad term of genetic modification includes genetic
engineering, which is “the genetic alteration of embryos before
implantation in the womb, or, more radically, the genetic alteration of
sperm or ova before conception. In theory scientists could add genes
that produce desirable traits (such as health, beauty, and intelligence)
or subtract genes that produce undesirable traits (such as disease).”41
There are several methods of trying to produce children naturally with
superior genetic endowments, such as: “somatic enhancements in
adults and children, pre-conception enhancement, selective abortion,
embryo selection, and germline enhancement.”42 However, this paper
will focus primarily on the direct manipulation of genes such as gene
insertion or deletion. These techniques, otherwise known as RGBs
constitute a genetic intervention: “(1) when it is undertaken for the
purpose of improving a characteristic or capability that, but for the
enhancement, would lie within what is generally accepted as ‘normal’
range for humans; or (2) when it installs a characteristic or capability
that is not normally present in humans.”43 These interventions are
still futuristic in many respects and do not currently allow parents to
screen or enhance characteristics such as height, eye color,
intelligence, or a myriad of other traits; however, the technology is
advancing rapidly and as one scientist and futurist observes the time

39. See BEYOND THERAPY, supra note 12, at 29.
40. See Anthony W.S. Chan et al., Foreign DNA Transmission by ICSI: Injection of
Spermatozoa Bound with Exogenous DNA Results in Embryonic GFP Expression and Live
Rhesus Monkey Births, 6 MOLECULAR HUM. REPROD., no. 1 26-33 (2000); Yuyu Niu et al.,
Generation of Gene-Modiﬁed Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in
One-Cell Embryos, 156 CELL 836 (2014) (stating that researchers in China have created
genetically modified monkeys using a new method of precise gene targeting known as Crispr,
which can alter a DNA sequence at a specific location within a genome).
41. KERRY L. MACINTOSH, ILLEGAL BEINGS: HUMAN CLONES AND THE LAW 41 (2005).
42. Mehlman, supra note 21, at 524.
43. Id. at 523.
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to address these challenges has arrived:
The coming challenges of human genetic enhancement are not
going to melt away; they will intensify decade by decade as we
continue to unravel our biology, our nature, and the physical
universe. Humanity is moving out of its childhood and into a
gawky, stumbling adolescence in which it must learn not only to
acknowledge its immense new powers, but to figure out how to use
them wisely. The choices we face are daunting, but putting our
44
heads in the sand is not the solution.

The social, ethical, and legal challenges of genetic enhancement
require acknowledgement, but more importantly, recent
advancements in biotechnologies such as germline engineering
represent a paradigm shift—an early-stage embryo that can be
genetically enhanced prior to IVF implantation will likely have
profound implications that will redefine humanity. Three such
technologies will be discussed in the context of genetic engineering:
(1) gene transfer or somatic gene therapy, (2) germline engineering or
Inheritable Genetic Modification (IGM), and (3) Human Artificial
Chromosomes (HACs).
1. Somatic Gene Therapy
Research and development in somatic gene therapy has
responded to inheritable genetic diseases in existing adults that have
been identified as a result of the completion of the HGP. Currently,
first generation gene therapy technology targets cells other than
embryo or sperm cells and works by targeting common monogenic
diseases such as Duchenne muscular dystrophy and cystic fibrosis.45
The process involves transferring normal or healthy cells into the
somatic cells or tissue of the patient, producing genetic changes that
are restricted to the individual and not inheritable to future
offspring.46 More specifically, the process “involves physical
(microinjection), chemical (charged lipid carriers of DNA), and viral
methods to introduce the normal gene in chosen target cells.”47 Once
the injection has replaced the abnormal or missing gene, the gene is
expressed by “viral ‘vectors’ containing the inserted therapeutic DNA

44. STOCK, supra note 3, at 17.
45. See S. M. Selkirk, Gene Therapy in Clinical Medicine, 80 POSTGRADUATE MED. J.
560, 560-70 (2004); see also Donald B. Kohn & F. Candotti, Gene Therapy Fulfilling its
Promise, 360 NEW ENG. J. MED. 518, 518-21 (2009).
46. See STOCK, supra note 3, at 38.
47. MERGES ET AL., supra note 18, at 612.
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[which] are attenuated or modified versions of viruses that are
incapable of replicating in the patient, but retain the ability to
efficiently deliver DNA to the cell. These ‘vectors’ also contain
promoters that turn the normal gene on and off.”48 Past gene therapy
clinical trials have achieved little success, primarily because the
human body is made up of trillions of cells and for the gene therapy to
be effective, millions of cells need to be altered.49 Furthermore, with
the death of Jesse Gelsinger in 1999, while participating in a genetransfer clinical trial, greater regulatory oversight of gene therapy has
been imposed by the U.S. Food and Drug Administration (FDA).50
However, second generation gene therapy technologies may
prove more successful, because they target the incorporation of genes
into the cell nucleus using a Trojan horse approach, where “[i]nstead
of using a cellular virus to transfect the cells, this approach would
introduce gene sequences by ‘disguising’ them as a molecule
recognized by the cell and passing them through the cell
membrane.”51 Gene transfer techniques face two principal obstacles
to their safe and effective use: “[F]irst, the exact locations in the host
DNA into which new genetic information is inserted and, second, the
extent to which the new genes are expressed in the right cells at the
correct developmental time (without inducing other unwanted gene
expression or altered regulation of resident genes).”52 These obstacles
have led researchers to experiment with other methods of gene
transfer, such as anti-genes and germline engineering that, unlike
somatic cell therapy, only requires gene modification once to the
reproductive cells of the embryo.53
2. Germline Engineering or Inheritable Genetic
Modification (IGM)
Germline engineering or the term “germline” refers to the
“germ” or “germinal” cells of the eggs and sperm that are targeted for
genetic modification.54
Advances in biotechnology raise the
possibility that ARTs such as PGD may move beyond simply
48.
49.
50.
51.
52.
53.
54.

Id.; see REPRODUCTION AND RESPONSIBILITY, supra note 5, at 105.
See FUKUYAMA, supra note 7, at 76.
See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 113.
MERGES ET AL., supra note 18, at 612.
REPRODUCTION AND RESPONSIBILITY, supra note 5, at 107.
See LEE M. SILVER, REMAKING EDEN 273 (1998).
See ASS’N OF REPRODUCTIVE HEALTH PROFESSIONALS, HUMAN CLONING AND
GENETIC MODIFICATION: THE BASIC SCIENCE YOU NEED TO KNOW, available at
http://www.arhp.org/uploadDocs/cloning.pdf [hereinafter ARHP].
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diagnosing or selecting embryos for particular traits, to genetic
modification or engineering embryos for desired characteristics by
changing the genes in a progenitor’s gametes.55 Current germline
engineering technology represents such a shift in human reproduction
as it incorporates normal cells into the germline or reproductive cells,
essentially becoming part of the permanent genome of the offspring,
which unlike somatic gene therapy would be passed onto the next
generation through reproduction.56
This multistep germline
modification process includes: (1) using IVF to create a single-cell
embryo or zygote that develops into the blastocyst stage; (2)
embryonic stem cells are removed from the blastocyst, and the stem
cell genes are modified using viral vectors; (3) modified stem cells
colonies are tested for successful incorporation of the new genes; (4)
a cloning process transfers the modified stem cell nucleus into an
enucleated egg cell; and finally (5) the newly constructed embryo
would then be implanted into a woman’s uterus and after gestation
would produce a genetically modified child.57
Although the science and technology required to enable parents
to choose the genetic traits and characteristics of their children
continues to remain speculative, researchers involved in recent
genetic modification studies of mice and primates58 believe scientific
breakthroughs are inevitably pushing us closer to germline
modification in humans.59
Recent experimental breakthroughs
demonstrating the technological feasibility of germline modification
in mice have shown researchers can use sperm and eggs grown from
Induced Pluripotent Stem Cells (iPSCs) for reproduction—a
breakthrough theorized by some scientists involved in the project that
could be applied not just to mice, but in other mammals as well,
including humans.60 In a second recent scientific breakthrough in
germline modification, a new generation of genetically modified mice
were developed using Haploid Embryonic Stem Cells (haESCs); a
technique that researchers speculated could be used in the future to
correct genetic diseases in germ cells not just of mice, but of humans,

55. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 106.
56. See ARHP, supra note 54; see also MERGES ET AL., supra note 18, at 612.
57. See ARHP, supra note 54.
58. See Anthony W.S. Chan et al., Transgenic Monkeys Produced by Retroviral Gene
Transform into Mature Oocytes, 291 SCIENCE 309, 309-12 (2001).
59. See Katsuhiko Hayashi et al., Offspring from Oocytes Derived from in Vitro
Primordial Germ Cell–Like Cells in Mice, 338 SCIENCE 971, 971 (2012).
60. See id.
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too.61 Finally, biologists have recently succeeded in cloning human
stem cells by reprogramming somatic cells into pluripotent embryonic
stem cells (ESCs) through somatic cell nuclear transfer (SCNT).62
This groundbreaking technique produces human stem cells without
the ethical implications that accompany the creation and destruction
of human embryos—which could have significant implications for
research of pluripotent stem cell regenerative medicines.63 These
scientific breakthroughs illustrate proponents’ arguments that IGM is
not only scientifically feasible, but could also be used to allow
couples to avoid passing on serious genetic diseases, and have healthy
offspring that is genetically related to both parents.64
Proponents of IGM such as Stock, reiterate that “[g]ermline
engineering represents a shift in human reproduction, but as effective
somatic therapies become common, reduced public concern about
genetic interventions in general will smooth the way for a move from
screening and selecting embryos to actually manipulating them.”65
However, critics of human germline manipulation “frequently point to
the risks of passing on genetic errors to future generations. But even
if errors are entirely preventable, making our early genetic
modifications permanent parts of the human genome pool would be
foolish.”66 Opponents such as Fukuyama are in limited agreement
with Stock’s perspective that germline engineering represents
potentially the most consequential development in biotechnology.
“The reason for this is that human nature is fundamental to our
notions of justice, morality, and the good life, and all of these will
undergo change if this technology becomes widespread.”67 Yet, both
proponents and advisory agencies recognize the many shortcomings
of germline engineering, and recommend that even if such genetic

61. See Hui Yang et al., Generation of Genetically Modified Mice by Oocyte Injection of
Androgenetic Haploid Embryonic Stem Cells, 149 CELL 605, 605-17 (2012); see also Wei Li et
al., Androgenetic Haploid Embryonic Stem Cells Produce Live Transgenic Mice, 490 NATURE
407 (2012), available at http://dx.doi.org/10.1038/nature11435. From Embryonic Stem Cells, a
Sperm Replacement and Easier Path to Genetic Modification, PHYS.ORG (Apr. 26, 2012),
http://phys.org/news/2012-04-embryonic-stem-cells-sperm-easier.html.
62. See Masahito Tachibana, et al., Human Embryonic Stem Cells Derived by Somatic
Cell Nuclear Transfer, 153 CELL 1228, 1228-38 (2013).
63. See Thomas A. Rando, Stem Cells, Ageing and the Quest for Immortality, 441
NATURE 1080, 1080-86 (2006); Katharine Brown et al., SIRT3 Reverses Aging-Associated
Degeneration, 3 CELL REP. 319, 319-27 (2013).
64. See STOCK, supra note 3, at 56; see also BEYOND THERAPY, supra note 12, at 5.
65. STOCK, supra note 3, at 39.
66. Id. at 69.
67. FUKUYAMA, supra note 7, at 82-83.
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errors could be reversed, safer alternatives should be pursued that
minimize potential germline risks.68
3. Human Artificial Chromosomes (HACs)
The discussion surrounding current somatic gene therapy and
germline genetic engineering technologies looks to minimize the
safety risks, complexity, and costs associated; while maximizing
flexibility, general application, and future technological adaptation.
Researchers looking beyond current genetic engineering
developments believe an answer has emerged in the form of a
technology called Human Artificial Chromosomes (HACs).
Scientists predict HACs could be the archetypal futuristic answer to
all the problems of expensive, complex, and risky gene transfer
technologies. However, HACs are not a relatively new technology,
but rather were introduced in 1997, in a research article that first
described the process of “combined long synthetic arrays of alpha
satellite DNA with telomeric DNA and genomic DNA to generate
artificial chromosomes in human HT1080 cells.”69 This fascinating
introductory research claimed that, “[t]his first-generation system for
the construction of human artificial chromosomes should be suitable
for dissecting the sequence requirements of human centromeres, as
well as developing constructs useful for therapeutic application.”70
Research has developed slowly over the last decade, and focused
primarily on gene delivery and transfer into stem cells.71 However,
recent scientific advancements have stirred excitement with
breakthroughs in gene therapy that have found HACs “exhibit several
potential characteristics desired for an ideal gene delivery vector,
including stable episomal maintenance and the capacity to carry large
genomic loci with their regulatory elements, thus allowing the
physiological regulation of the introduced gene in a manner similar to
that of native chromosomes.”72 These breakthroughs with HAC
research in animals highlight the technology’s potential maturity and
future development, in contrast to several aforementioned genetic

68. See FRANKEL & CHAPMAN, supra note 32.
69. John J. Harrington et al., Formation of De Novo Centromeres and Construction of
First-Generation Human Artificial Microchromosomes, 15 NATURE GENETICS 345, 345, 355
(1997).
70. Id.
71. See Xianying Ren et al., Human Artificial Chromosome Vectors Meet Stem Cells, 2
STEM CELL REV. 43, 43-50 (2006).
72. Y. Kazuki et al., Refined Human Artificial Chromosome Vectors for Gene Therapy
and Animal Transgenesis, 18 GENE THERAPY 384, 384-93 (2011).
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engineering technologies.73
Proponents of genetic modification technologies propose
widespread adoption will require generalized methods for germline
modification and insertion, a problem in which the introduction of
HACs could be the answer researchers have been searching for. The
process would involve inserting a new chromosome pair (numbers 47
and 48) into our genome that would act as framework or platform in
which to add or remove genetic modules, instead of trying to modify
the genes on one of our present 46 chromosomes.74 Compared to
previous unreliable genetic modification techniques such as gene
therapy, an artificial chromosome would provide a generalized and
reproducible framework for adding and removing genetic material to
cells, that could produce a reliable and potentially “safe” human
germline technology. Proponents argue that such a technology would
revolutionize the conception of reproduction, and create a
marketplace where:
Parents will want the most up-to-date genetic modifications
available. Were these prospective parents’ own modifications
scattered through their chromosomes, cleaning them out and
upgrading them would be tricky, but with changes confined to an
auxiliary chromosome, a parent could simply discard the entire
75
thing and give his or her child a new version.

An advantage of such a technique could provide for “gene-packs” that
could allow for hundreds, if not thousands of unique gene
modifications to an embryo.76 Based on proponents’ futuristic
predictions, HACs could solve many of the problems plagued by
current genetic engineering technologies, and provide parents the
option of passing on their chromosomal genetic upgrades to their
children or discarding them.77 Futurists predict this technological
advancement if successful, would result in a profound transformation
of the human condition, because ultimately “it is a convergence of the
processes that will bring us as well as machines into being and shape
our natures. Human conception is shifting from chance to conscious
design.”78
73

See Yuwna Yakura et al., An induced pluripotent stem cell-mediated and integration-free
factor VIII expression system, 431 BIOCHEMICAL AND BIOPHYSICAL RESEARCH
COMMUNICATIONS 336 (2013).
74. See STOCK, supra note 3, at 66.
75. Id. at 69-70.
76. See SILVER, supra note 53, at 271.
77. See STOCK, supra note 3, at 70.
78. Id. at 75.
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However, opponents of genetic modification such as Leon Kass,
Chair of the President’s Council on Bioethics, concede that such
futuristic artificial chromosomal genetic modifications such as HACs,
would be a safer alternative to the known risks of gene therapy or
inheritable alternatives such as IGM.79 Kass concedes that HACs
(assuming a hypothetical agreement on their perceived safety), would
have greater benefits over current genetic engineering technologies,
because the creation and injection of artificial chromosomes would
essentially enable “the new ‘better’ genes [to] be packaged in small,
manufactured chromosomal elements that, on introduction into cells,
would not integrate into any of the normal forty-six human
chromosomes. Such artificial chromosomes could, in theory, be
introduced into ova or zygotes without fear of causing new
mutations.”80 In realizing the potential benefits of HACs, Kass is
careful to recognize the technology is far from practical, and there
exist significant challenges to overcome, such as the fact that genes
introduced on an artificial chromosome “would now be present in
three copies (one from mother, one from father, and one on the extra
chromosome) instead of the usual two, throwing off the normal
balance of gene copies among all the genes. The consequences of
such ‘triploidy’ [could] be deleterious . . . .”81 Therefore, Kass’s
superficial support of HACs over alternative genetic engineering
technologies may simply be in response to the current unavailability
of the technology, and belief that the safety risks will always pose a
barrier to its adoption. However, as research and development of
HACs continues, only time will tell if the technology materializes into
the futuristic visions proposed by proponents of genetic engineering,
or as suggested by opponents, into another unrealized speculative
technology with promise, but with far too many practical hurdles to
overcome to become a reality.82
79. BEYOND THERAPY, supra note 12, at 37.
80. Id.
81. Id. Proponents would likely argue any reproductive safety concerns from opponents
in respect to the feasibility of RGBs such as HACs, could simply be solved by removing or
disabling the HACs, or inserting an anti-germline birth-control or sterilization module to prevent
an inadvertent ‘triploidy’ or IGM.
82. See FUKUYAMA, supra note 7, at 77; cf. Def. Advanced Research Projects Agency
(DARPA), ST13B-001: Advanced Tools for Mammalian Genome Engineering, SBIR/STTR
(July 26, 2013), https://www.sbir.gov/node/411230 (defining DARPA’s objective to “[i]mprove
the utility of Human Artificial Chromosomes (HACs) by developing new selectable metabolic
markers for use in human cells, new high-fidelity methods for inserting DNA constructs of at
least 50,000 base pairs (bp) in length into defined genomic loci, and new methodologies for
facile intercellular genome transplantation”).
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II. THE SOCIAL AND BIOETHICAL IMPLICATIONS
There are numerous social and ethical concerns proposed by
both proponents and opponents of Reproductive Genetic
Biotechnologies (RGBs) that form the extensive and varied
controversial public debate surrounding reproductive technologies.
The public debate put forward by both proponents and opponents of
genetic modification span a broad range of contentious issues that are
beyond the scope of this paper which include: constitutional
reproductive issues, gender selection, eugenics, cloning, and abortion.
Therefore, the following discussion will be divided into two sections.
First, proponents’ principle arguments in support of genetic
engineering will be briefly introduced.
Second, opponents’
arguments against genetic engineering will be discussed, followed by
corresponding rebuttals from proponents.
A. Proponents of Genetic Engineering
Proponents of RGBs have advanced numerous social, ethical,
legal, and philosophical justifications. Yet, many of these arguments
advocating support of genetic engineering are articulated in rebuttals
to opponents’ arguments against RGBs—discussed later in the paper
in response to opponents’ various arguments. However, for the
purposes of lucidity, the following discussion will focus narrowly on
only four of proponents’ most salient points: evolution, inevitability,
defining life, and feasibility.
First, proponents argue that humans have always acted in ways
that affect the evolution of our species. “Human action has shaped
human biology and altered the genome as long as there have been
human beings: a series of non-biomedical enhancements of human
capacities, from the agrarian revolution . . . has trigged processes of
natural selection and mixed previously isolated gene pools.”83 From
this perspective, RGBs are just the next step along a path long since
taken. Moreover, a case can be made that humankind’s modern day
socio-technological progress has exceeded its outdated biology,
rendering it necessary to accelerate our biological evolution. Gregory
Stock articulates this point stating, “It is rather poignant that we
cannot yet apply technology more directly to our biological selves,
because the advances in transportation, telecommunications, and
other areas that enable us to transcend some of our bodily limits give

83. ALLEN E. BUCHANAN, BEYOND HUMANITY?: THE ETHICS OF BIOMEDICAL
ENHANCEMENT 1-2 (2011).
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us the idea that we should also be able to stay our eventual aging and
decay.”84
Second, prominent proponents such as Julian Savulescu, argue in
addition to Stock that “[g]enetic selection to determine how our
children look, think and act isn’t recklessly playing God . . . . It’s a
gift to future generations.”85 Savulescu articulates this modernist
ideology of inevitability, an argument often posited by proponents,
that “[i]f we have the power to intervene in the nature of our
offspring—rather than consigning them to the natural lottery—then
we should. Surely trying to ensure that your children have the best, or
a good enough, opportunity for a great life is responsible
parenting?”86 This argument is founded on the conceptualization that
if humankind has the ability to better our children, such
improvements will be an inevitable consequence of providing for our
offspring. Whether the improvement occurs pre-gestation or post
gestation is irrelevant, because society is still trying to care for their
children. This distinction of improvement analyzed from proponents’
perspective, lends credibility to the inevitability argument that,
“[w]hether we like it or not, the future of humanity is in our hands
now. Rather than fearing genetics, we should embrace it. We can do
better than chance.”87
Third, futurist proponents such as Lee Silver argue opponents
maintain a controversial defect in their definition in human life, and
that there is a serious flaw in the logical progression that leads people
to adopt the idea that the “essence” of human life is contained within
our genetic material.88 According to Silver, the flaw is caused by the
inability of opponents to separate the different meanings of the word
“life” at the level of the individual embryo and at the level of human
consciousness.89 This extremely important, yet controversial and
complex discussion of attempting to define exactly when life begins,
from either a theological or scientific perspective, is far beyond the
scope of this paper. However, this important principle remains a
fundamental differentiation between proponents and opponents, and
provides further context to understanding justifications for or against

84.
85.

STOCK, supra note 3, at 33.
Julian Savulescu, The Maverick: It’s Our Duty to Have Designer Babies, READER’S
DIGEST (2012) (on file with Santa Clara High Technology Law Journal).
86. Id.
87. Id.
88. See SILVER, supra note 53, at 276.
89. See id.

KELLY

322

4/2/2014 11:02 PM

SANTA CLARA HIGH TECH. L.J.

[Vol. 30

RGBs. Silver and other proponents recognize the difficulty and
futility of influencing opponents’ definition of human life. As a
result, proponents typically avoid advancing such arguments in favor
of focusing on the benefits RGBs can bring to existing human life and
the feasibility of the technology for prevention of genetic disease.
Fourth, proponents reject assertions that genetic modification is
still highly speculative and thus not deserving of rational discourse.
The crucial enabling technology for germline engineering was
discovered in 1980,90 and since then has seen advancements in
“knocking out” or silencing genes.91 These advancements were
discovered in 2001, which include a new classification of ribo-nucleic
acids (RNAs) that selectively silence genes after transcription.92
Researchers introduce a specific germline modification in a mouse
gene by injecting the mouse’s fertilized eggs with DNA and grow
embryonic stem cells encoding the intended change.93 Researchers
then inject the selected embryonic stem cells into a blastocyst, which
is implanted in the foster mother mouse.94 After gestation, the mother
gives birth to chimeric mice that when mated with normal mice can
give birth to mice with the targeted gene, thereby producing a “knockout strain” in the subsequent mouse generation.95 Some proponents
have considered this development of knocking-out genes in the next
generation of mice as a cornerstone of germline engineering research
that will one day enable parents to select and manipulate the genetics
of their children.96 Moreover, proponents often synthesize these four
main arguments when predicting future research and development in
genetic engineering will inevitably lead to human genetic
manipulation. Therefore, it’s argued that “inevitability” of RGBs
defeat opponents’ arguments of feasibility, because such
advancements are the logical conclusion of our ongoing evolution in
reproductive biology.97

90. See Jon W. Gordon et al., Genetic Transformation of Mouse Embryos by
Microinjection of Purified DNA, 77 PROC. NAT’L ACAD. SCI. no. 12 7380, 7380-84 (1980).
91. See Goran K. Hansson, Advanced Information: Gene Modification in Mice,
NOBELPRIZE.ORG
(2007),
http://www.nobelprize.org/nobel_prizes/medicine/laureates/2007/advanced.html
[hereinafter
Nobel].
92. See Jennifer Couzin, Breakthrough of the Year, 298 SCIENCE 2296, 2296 (2002).
93. See Nobel, supra note 91; see also STOCK, supra note 3, at 50.
94. See Nobel, supra note 91.
95. See id.; see also STOCK, supra note 3, at 50.
96. See STOCK, supra note 3, at 50.
97. See id. at 61.
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1. Procreative Liberty and Genetic Engineering
Some proponents of RGBs argue that parents should be free to
choose the genetic disposition of their children. John Robertson, who
takes a moderate perspective on genetic engineering, 98 classifies
procreative liberty proponents of RGBs as either radical libertarians
or modern traditionalists.99 Modern traditionalists hold “reproductive
choice in a liberal, rights-based society is a basic freedom, including
the use of genetic and reproductive technologies that are helpful in
having healthy, biologically related offspring.”100 Radical libertarians
would arguably support any form of genetic modification regardless
of its purpose,101 based on the fundamental principles of individual
liberty, autonomy, and freedom, whereas modern traditionalists’
“acceptance of reproductive and genetic technologies . . . exists only
insofar as they aid the task of successful reproduction, and do not
directly harm offspring, families, women, society, or others.”102 This
perspective balances the benefits of non-medical genetic selection
against the perceived costs and safety risks involved in such a
selection. Therefore, justification for positive genetic modification of
our children’s genes, from a modern traditionalist perspective, would
depend on the parent’s reasons and whether it occurs as a result of
therapeutic alteration or non-therapeutic alteration.103
a. Therapeutic Alteration
First, arguments advanced in support of IGM for therapeutic
purposes focus on allowing couples to avoid passing on serious
genetic diseases, such as “sickle cell anemia, Tay Saches disease, or
cystic fibrosis.”104 However, opponents in rebuttal, claim other less
risky methods already exist to accomplish the same goal, such as
PGD that requires no manipulation of the germline.105 Secondly,
proponents posit that IGM can allow couples that both share a

98. See John A. Robertson, Symbolic Issues in Embryo Research, HASTINGS CENTER
REP., Jan.-Feb. 1995, at 37.
99. Robertson, supra note 16, at 446, 474.
100. Id. at 446.
101. See id. at 474. Eisenstadt v. Baird, 405 U.S. 438, 453 (1972) (“If the right of privacy
means anything, it is the right of the individual, married or single, to be free from unwarranted
governmental intrusion into matters so fundamentally affecting a person as the decision whether
to bear or beget a child.”).
102. Robertson, supra note 16, at 446.
103. See id.
104. See id. at 476.
105. See id.
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defective gene to have a healthy child that is related to both of them,
rather than produce no child at all.106 Yet, opponents still reject such
assertions, because such cases are likely to be a very rare and small
percentage to warrant IGM.107 Lastly, proponents conclude that
human IGM clinical trials need to continue in order to establish that
the science and process behind therapeutic modification becomes safe
and effective.108 Therefore, any inherent risk or harm to the child, if
minimized, would be a generally acceptable risk of medical
progress.109
b. Non-therapeutic Alteration or Enhancement
First, proponents argue that if IGM could allow couples to
“enhance” their children to be healthier, more athletic, intelligent, or
attractive, such enhancement is supported by procreative liberty
whether it occurs pre-birth or post-birth.110 However, opponents
refute such claims, because non-therapeutic enhancement would
likely be permanent and affect future generations, and because genetic
modifications are very different in quality and kind than post-birth
enhancements.111
Second, proponents recognize the inherent threat to equality if
genetic enhancement becomes so essential for reproduction it would
require parents to engage in a genetic arms race for their children.112
Many think that it is inherently unfair for some people to have
access to technologies that can provide advantages while others,
less well-off, are forced to depend on chance alone. I would agree.
It is inherently unfair. But American society adheres to the
principle that personal liberty and personal fortune are the primary
determinants of what individuals are allowed and able to do.
Anyone who accepts the right of affluent parents to provide their
children with an expensive private school education cannot use
‘unfairness’ as a reason for rejecting the use of reprogenetic
113
technologies.

Therefore, proponents and opponents would likely agree that
there exist serious risks of genetic social stratification, but it is unclear
106.
107.
108.
109.
110.
111.
112.
113.

See id.
Id.
See Robertson, supra note 16, at 476-77.
Id.
See id. at 478-79.
Id.
See id. at 479.
SILVER, supra note 53, at 10-11.
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at what point proponents agree such risks warrant government
regulation. In order to understand these complex issues and frame
solutions to these future genetic societal problems, risks must also be
examined in the context of post-humanism.
2. Our Post-Humanism Future
Many proponents of genetic engineering suggest if humankind
were to adopt genetic engineering technologies that enable parents to
choose the genetic characteristics of their children, and were to take
the science a step further—to choose desirable genetic enhancements
and abilities, such as sharper eyesight, better hearing, stronger
immune systems, or greater intelligence—would the child still be
considered human?114 When framing humankind’s existence and
identity in this continually evolving context, one must accept that due
to constantly changing somatic and germ-line mutations, the genetic
composition of who we are today, is not who we were yesterday.
This reconceptualization of existence is necessary to understand the
post-humanist movement’s principles as humankind looks to new
frameworks to define life. Ray Kurzweil attempts to answer the
question of identity in that, “I am rather like the pattern that water
makes in a stream as it rushes past the rocks in its path. The actual
molecules of water change every millisecond, but the pattern persists
for hours or even years.”115 This poignant example forces us to reexamine the importance of our ideological belief that we define our
existence not by the atoms or particles that make our bodies, but
rather the pattern of our life form that existentially creates the essence
of our being. In that sense, if we were to alter our physical bodies
with futuristic RGBs such as those proposed, after such radical
genetic modifications, would we continue to exist or simply be
replaced by somebody or something else? “At bare minimum, even if
enhancement brings such goodies as superhuman intelligence and
radical life extension, it must not involve the elimination of any of
your essential properties. For in that case . . . they would not be
experienced by you—they would be experienced by someone else.”116
This quintessential point illustrates that this reconceptualization of

114. See generally GREGORY STOCK & JOHN CAMPBELL, ENGINEERING THE HUMAN
GERMLINE: AN EXPLORATION OF THE SCIENCE AND ETHICS OF ALTERING THE GENES WE PASS
TO OUR CHILDREN (2000).
115. KURZWEIL, supra note 11, at 383.
116. SCIENCE FICTION AND PHILOSOPHY: FROM TIME TRAVEL TO SUPERINTELLIGENCE
244 (Susan Schneider, ed., 2009).
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human existence as a result of the ultimate genetic enhancements,
could lead to enhancing our children beyond their essential properties,
which would be tantamount to suicide. It is precisely these types of
complex philosophical issues surrounding autonomy and existence
that require the social and ethical implications of this post-humanism
movement to be considered as equally important as the progression of
the technologies themselves. If humankind ever chooses to adopt the
benefits of this transformation, how it chooses to define the human
condition and its impact on society will ultimately determine if RGBs
are considered good or bad.117 The salience of this post-humanism,
and evolutionary genetic prospective has also been articulated from
philosophers such as Friedrich Nietzsche:
All beings so far have created something beyond themselves; and
do you want to be the ebb of this great flood and even go back to
the beasts rather than overcome man? What is the ape to man? A
laughingstock or a painful embarrassment. And man shall be just
that for the overman: a laughingstock or a painful embarrassment.
You have made your way from worm to man, and much in you is
still worm. Once you were apes, and even now, too, man is more
118
ape than any ape.

Whether man is in fact still an ape in the context of our current
evolutionary perspective, or has already achieved natural evolutionary
perfection is one of the fundamental dichotomies between proponents
and opponents of RGBs. This divergence of ideologies is further
explored by the following arguments advanced by opponents through
their justifications of rejecting genetic modification technologies.
B. Opponents of Genetic Engineering
First, opponents of RGBs argue that public perception based on
the pre-existing safe and successful biotechnological results of ARTs
such as PGD, “may already be shifting parental and societal attitudes
toward prospective children: from simple acceptance to judgment and
control, from seeing a child as an unconditionally welcome gift to
seeing him as a conditionally acceptable product.”119 However, such
117. See generally JAMES HUGHES, CITIZEN CYBORG: WHY DEMOCRATIC SOCIETIES
MUST RESPOND TO THE REDESIGNED HUMAN OF THE FUTURE (2004) (Advocating a moderate
perspective of democratic post-humanism, where genetic engineering technologies will radically
improve humankind, but only if we can democratically regulate their use, and make them
equally available in free societies).
118. FRIEDRICH NIETZSCHE, THE PORTABLE NIETZSCHE 124 (Walter Kaufmann, ed. trans.,
Penguin Books 1977).
119. BEYOND THERAPY, supra note 12, at 35.
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“child product” arguments against PGD hold little weight in public
perception. The technology has already proven the procedure safe
and effective; more than 1,000 babies have born worldwide120 without
any noticeable impact on social attitudes toward children.
Opponents’ perceptions may be accurate that public attitudes in
support of PGD are shifting away from prevention of genetic
diseases, to the selection of desired traits as the number of PGD
procedures performed is increasing.121 However, proponents respond
that regardless of whether PGD is becoming a normative technology
in society, and whether that transformation is perceived as a positive
or negative, both parties agree that the earlier screening occurs, the
more likely it is that prospective parents will have healthy
offspring.122
Second, John Robertson characterizes many opponents of RGBs
as strict traditionalists.123
A strict traditionalist “holds that
reproduction is a gift from God, resulting from the loving intimacy of
two persons. They receive the gift of an embryo, fetus, and then child
who is to be unconditionally cherished for its own sake.”124 A leading
contemporary of strict traditionalism is Leon Kass, who postulates,
“[w]hat’s at issue is not the crude old power to kill the creature made
in God’s image but the attractive science-based power to remake
ourselves after images of our own devising.”125 Kass uniquely
articulates the social, ethical, and philosophical implications
surrounding the debate of genetic modification from a strict
traditionalist perspective and argues strenuously against genetic
enhancement primarily because of its enormous potential to interfere
with and diminish the purity of human nature.126 As he explains:
In a word, one major trouble with biotechnical (especially mental)
‘improvers’ is that they produce challenges in us by disrupting the
normal character of human being-at-work-in-the-world, what
Aristotle called energeia psyches, activity of soul, which when fine
and full constitutes human flourishing.
With biotechnical
interventions that skip the realm of intelligible meaning, we cannot
really own the transformations nor experience them as genuinely
ours. And we will be at a loss to attest whether the resulting

120.
121.
122.
123.
124.
125.
126.

See JUDITH F. DAAR, REPRODUCTIVE TECHNOLOGIES AND THE LAW 305 (2006).
See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 90.
See Robertson, supra note 16, at 460.
See id.
Id. at 442.
BEYOND THERAPY, supra note 12, at 10.
See id.
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conditions and activities of our bodies and our minds are, in the
127
fullest sense, our own as human.

In this passage, Kass characterizes genetic enhancement
biotechnologies as transformations that are not our own and,
therefore, not human. Thus, Kass frames the quintessential question,
“‘What is biotechnology for?’ but also, ‘What should it be for?’”128
The term biotechnology is understood to be “bigger than its processes
and products; it is a form of human empowerment. By means of its
techniques (for example, DNA sequences), biotechnology empowers
us human beings to assume greater control over our lives, diminishing
our subjection to disease and misfortune, chance and necessity.”129 It
is precisely this enthusiasm for biotechnology that attempts to answer
the question what biotechnology is for, with the knowledge that the
“discoveries of biologists and the inventions of biotechnologists are
steadily increasing our power ever more precisely to intervene into
the workings of our bodies and minds and to alter them by rational
design.”130
The public debate surrounding these emerging
technologies, from the perspective of strict traditionalists, has already
provided unwanted answers to these rhetorical questions expressed
simply by the “[v]ast numbers of people and their families [who]
ardently await cures for many devastating diseases and eagerly
anticipate relief from much human misery. We will surely welcome .
. . new technological measures that can bring us healthier bodies,
decreased pain and suffering, peace of mind, and longer life.”131
1. Going Beyond “Therapy” for “Enhancement”
In contrast to proponents’ enthusiasm of biotechnology,
opponents express caution in adopting these new biotechnologies that
promise to usher in an era of healthier bodies, simply because “the
prospect of genetic engineering, though welcomed for treatment of
inherited genetic diseases, raises for some people fears of eugenics or
worries about ‘designer babies.’”132 These fears form the crux of the
strict traditionalist perspective and Kass’s argument—a perspective
which is predicated on the concern of the emerging juxtaposition of

127. Leon R. Kass, Ageless Bodies, Happy Souls: Biotechnology and the Pursuit of
Perfection, 1 NEW ATLANTIS 9, 24 (2003).
128. BEYOND THERAPY, supra note 12, at 1.
129. Id. at 2.
130. Id. at 5.
131. Id.
132. Id.
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biotechnology applications in traditional medicinal use for healing,
and those that go “beyond therapy,” thus improving the human
condition for enhancement purposes. Kass suggests that these broad
concerns, “attach especially to these uses of biotechnology that go
‘beyond therapy,’ beyond the usual domain of medicine and the goals
of healing, uses that range from the advantageous to the frivolous to
the pernicious.”133 Kass’s concerns justifiably find support in the
public debate, primarily because his ideologies resonate with
society’s cultural and historical understanding that enhancement for
enhancement sake, goes beyond the purpose of healing and raises
important theological concerns that “[n]ot everyone likes the idea of
‘remaking Eden’ or of ‘man playing God.’”134
Kass bemoans the tendency to dismiss these issues. In his
words, “questions raised by efforts to ‘improve on human nature’
seem abstract, remote, and overly philosophical, unfit for public
policy; indeed, many bioethicists and intellectuals believe either that
there is no such thing as ‘human nature’ or that altering it is not
ethically problematic.”135 However, Kass notes that the distinction
between therapy and enhancement is not too remote or abstract—
technologies that alter “human nature,” such as cosmetic surgery and
performance enhancing drugs, are already pervasive in our society.136
Public attention is warranted now, before a wave of new and more
extreme technologies alter human nature and human society.137
a. Seeking Perfection
For these reasons strict traditionalists narrowly focus on the
implications of the “well-meaning and strictly voluntary uses of
biomedical technology through which the user is seeking some
improvement or augmentation of his or her own capacities, or, from
similar benevolent motives, of those of his or her children.”138 The
different motivations behind therapeutic alterations and nontherapeutic enhancements form an important cornerstone of
opponents’ arguments, because in effect they form the guideposts
between moral justification and condemnation.139
Strict

133.
134.
135.
136.
137.
138.
139.

BEYOND THERAPY, supra note 12, at 6.
Id. at 7.
Id.
See id. at 8.
See id. at 10.
BEYOND THERAPY, supra note 12, at 10.
See MICHAEL J. SANDEL, THE CASE AGAINST PERFECTION: ETHICS IN THE AGE OF
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constructionists perceive “[s]uch use of biotechnical powers to pursue
‘improvements’ or ‘perfections,’ whether of body, mind,
performance, or sense of well-being, is at once both the most
seductive and the most disquieting temptation.”140
Differentiating between these two ideologies of therapy and
enhancement arguably distinguish opponents’ Kantian philosophy,
where the ends do not justify the means. This moral perspective on
self-augmenting capabilities, or the idea of enhancement, is
understood as seeking something “better than normal” or human
perfection itself.141 This reflection illustrates the “perfectionist” strict
constructionist argument against RGBs, because such perfection or
enhancement can only be seen as a means to an end. Thus, those in
pursuit of perfection must distort the modern day intended purpose of
ARTs and RGBs, which is the prevention and curing of disease, in
order to alleviate suffering.142
b. Seeking Normality
Kass rejects proponents’ arguments that support RGBs based on
genetic inequality in order to pursue human normality.143 This
controversial idea of normality is defined by the libertarian argument
that the human condition and its capacities acquired at birth are no
more than a product of pure chance. As a result “[m]ost human
capacities fall along a continuum, or a ‘normal distribution’ curve,
and individuals who find themselves near the lower end of the normal
distribution may be considered disadvantaged and therefore unhealthy
in comparison with others.”144
Predictably, Kass simultaneously acknowledges and dismisses
the normality argument advanced by proponents of enhancement,
because even though normality may not be driven by “perfection,”
those who unluckily fall on the low-end of the culturally-relative
spectrum, exist as a result of human nature; therefore, “[a]lthough less
radical than the quest for ‘perfection,’ the quests for happiness,
success, and self-esteem, especially in our society, may prove to be
more powerful motives for an interest in using biotechnical power for

GENETIC ENGINEERING 8-18 (2007).
140. BEYOND THERAPY, supra note 12, at 10.
141. See id. at 14.
142. See id. at 12.
143. Id. at 131-34, 140, 281-82.
144. Id. at 18.
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purposes that lie ‘beyond therapy.’”145 Kass concedes that, given the
opportunity, “many of us might welcome biotechnical assistance in
improving our native powers of mind and body, many more people
will probably turn to it in search of advancement, contentment, and
self-satisfaction—for themselves and for their children.”146 Yet,
opponents are careful to differentiate that even though many people
would pursue enhancement if available and proven safe, further study
is still needed to determine the far-reaching implications, and whether
accessibility to these biotechnologies will be equitably distributed. If
such genetic enhancements are pursued without regard for its social
implications, opponents argue disastrous social consequences could
follow.147
c. Natural Limits Theory
Kass characteristically poses the quintessential question of
genetically engineering our children’s genes: “[w]hat parents would
not wish to enhance the life of their children, to make them better
people, to help them live better lives?”148 Parents fundamentally
strive to improve and better their children by means of clothing,
nutrition, education, and support until they become adults. It has been
this inherent concept of naturally improving our children that is under
scrutiny, argues opponents, because present and projected
biotechnologies will provide new and powerful means for improving
our children.149 The moral and philosophical questions raised in
response by Kass presuppose the improvement of our children, and
the means best suited to accomplish these goals are inherently limited
as a design of human nature. Yet opponents recognizes these
limitations are in actuality, inequalities placed on human nature itself:
[N]ature sets limits on what can be accomplished by education and
training alone. No matter how much we try to help, the tone-deaf
will need more training to learn to carry a tune, the short will be
less likely to excel at basketball, the irascible will have trouble
restraining their tempers, and the insufficiently smart will remain
150
handicapped for competitive college admissions.

If our children’s natural “equipment” is faulty or limited by

145.
146.
147.
148.
149.
150.

Id. at 19.
BEYOND THERAPY, supra note 12, at 19.
See id.
Id. at 25.
See id. at 27.
Id.
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means which will prevent them from realizing their true human
potential (either by subjective or objective determinism), parents will
naturally wish and seek out methods to improve or better their
children as they have always done. Improving our children in this
context is a socially conditioned maxim that requires no justification,
when “[e]ven before the coming of the present age of biotechnology,
we have used technological adjuncts to improve upon nature’s gifts.
We give our children supplementary vitamins, fluoridated toothpaste,
and, where necessary, corrective lenses or hearing aids.”151 These
culturally normative improvements and adaptations of our children’s
gifts provide little support to Kass’s “natural limits” theory, which is
further exacerbated by continued technological developments
enabling parents to “use biological means of improving their
[children’s] limited human capacity to resist disease: we immunize
our children against polio, diphtheria, and measles, among other
infectious diseases, by injecting them with attenuated viruses and
bacteria in the form of vaccines.”152
2. Safety Risks of Genetic Engineering
Finally, opponents question the post-human agenda on biological
and safety grounds. In order for genetic engineering to be done, “one
would first need to identify all (or enough) of the specific variants of
genes whose presence (or absence) correlates with certain desired
traits: higher intelligence, better memory, perfect pitch, calmer
temperament, sunnier disposition, greater ambitiousness, etc.”153
These socially normative “desired traits” of parents for their unborn
children, even if they were discovered, are genetic traits heavily
influenced by the external environment, which “are most certainly
polygenic, that is, traits (or phenotypes) that depend on specific genes
or their variants at several, perhaps many, distinct loci.”154 The
complexity of these polygenic and epigenetic gene interactions would
essentially prevent parents from choosing desired traits beyond simple
single gene interactions such as height, eye, or hair color.155
Furthermore, because many of the genes involved in the expression of

151.
152.

Id. at 28.
BEYOND THERAPY, supra note 12, at 28; see KATHLEEN S. SWENDIMAN, CONG.
RESEARCH SERV., RS21414, MANDATORY VACCINATIONS: PRECEDENT AND CURRENT LAWS
(2011).
153. BEYOND THERAPY, supra note 12, at 35.
154. Id.
155. See id. at 36.
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normal traits are “pleiotropic—that is, they influence many traits, not
just one—even a properly inserted gene introduced to enhance a
particular trait would often have multiple effects, not all of them for
the better.”156 For these reasons, opponents conclude that any attempt
to genetically modify or enhance normal “healthy” gametes or
embryos would be unsafe, infeasible, and ethically suspect.157
In response, proponents recognize that there exist numerous
polygenic and epigenetic safety concerns that need to be addressed.
However, if the technology is proven to be successful, it would only
be introduced if it were possible to block genetic transmission to the
next generation.158 Moreover, proponents understand that proving the
technology to be successful will require inherently risky and
unpredictable human clinical experimentation. Yet, proponents are
careful to argue that all medical progress does entail some risk within
generally accepted parameters, and genetic modification could be
reversed if problems occur.159 Furthermore, proponents argue that
when viewing RGBs as a form of medical progress, any arguments
against the use of medical assistance in reproduction would only be
justified if based on a theological or metaphysical perspective of
“natural” reproduction; essentially condemning all forms of
technological assistance.160 Unless opponents believe that any
interference with the natural process of reproduction is wrong, such
an argument against medical progress could not withstand scrutiny,
because societal technological advancements currently assist humans
with the limitations nature has placed on them. Proponents use this
perspective to justify their argument that utilizing ARTs and,
potentially, RGBs pre-birth to assist in the creation of life is no more
objectionable than using technologies post-birth to sustain or support
that life.161
In contrast to proponents who are excited that RGBs will usher
in a new era of human evolution, opponents such as Bill McKibben
argue that it is wrong to alter human nature.162 According to
McKibben, “What makes us unique is that we can restrain ourselves.
We can decide not to do something that we are able to do. We can set

156.
157.
158.
159.
160.
161.
162.

Id. at 37.
See id.
See STOCK, supra note 3, at 69.
See id. at 153.
See SILVER, supra note 53, at 275-76.
See Robertson, supra note 16, at 444.
See MCKIBBEN, supra note 13.
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limits on our desires. We can say ‘Enough.’”163 McKibben argues
we need to preserve humankind’s uniqueness before we lose our
capacity for restraint. As the availability of genetic enhancement
technologies becomes as ubiquitous in society as elective cosmetic
surgeries, or pharmaceutical enhancing drugs, the ability for
humankind to define and retain its “essential properties” will become
increasingly difficult.164 According to McKibben, we must question
not only our desire to improve, but also how we choose to reach that
goal.165
3. Inequality Concerns of Genetic Discrimination
If the proliferation of RGBs is only available to a select few who
can afford them, the consequences will likely divide society and
create two related problems: social inequality and unfairness.166 The
division will likely further perpetuate social inequality and further
entrench socio-economic stratification, because RGBs will initially
only be available to those who can afford the elective procedures
involved.167 IVF alone can cost an average of $37,000 per delivery;
the genetic manipulations of embryos required will add further
expense.168 Moreover, most health insurance does not cover IVF169
and is unlikely to cover add-ons such as the engineering of
embryos.170 Therefore, most people will not be able to afford RGBs.
Society could attempt to minimize the threat to equality by providing
universal coverage of genetic enhancements, or subsidizing their
availability to the genetically disadvantaged. Yet, such “utopian
eugenics”171 would be prohibitively expensive, because such
widespread access to enhancements that depended on IVF or PGD
would cost $120 billion per year for IVF services alone.172
Additionally, attempting to subsidize genetic enhancements would
require identifying genetically disadvantaged individuals and groups,

163. Id. at 205.
164. See id. at 109-17.
165. See MCKIBBEN, supra note 13.
166. See Mehlman, supra note 21, at 533-34.
167. See FUKUYAMA, supra note 7, at 81.
168. See Mehlman, supra note 21, at 530-31.
169. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 154-55; see also Judith F.
Daar, Accessing Reproductive Technologies: Invisible Barriers, Indelible Harms, 23 BERKELEY
J. GENDER L. & JUST. 18, 36-37 (2008).
170. See Mehlman, supra note 21, at 531.
171. See SILVER, supra note 53, at 261.
172. See Mehlman, supra note 21, at 532.
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which raise serous practical, moral, and political concerns.173
Furthermore, because society will not be able to provide everyone
with access to the same genetic enhancements the wealthy can
purchase, there would continue to be an inherent inequality.174
Employers and educators are an example of a constituency that
will likely face new challenges in determining fairness and
equitability in regulating standards for enhanced versus unenhanced
individuals.175 For example, studies show that people who are tall
and physically attractive are more likely to be hired and promoted
than people who are short or unattractive.176 Genetically enhanced
individuals could have an unfair advantage in competition for scarce
societal and economic resources such as aptitude-based employment,
or academic acceptance, because genetic enhancement could improve
characteristics that are arguably suited for success and well-being.177
Some commenters have even proposed futuristic scenarios in which
unequal access to RGBs “eventually create[s] a political system
dominated by a genetic aristocracy, or ‘genobility,’ that possesses a
lock on wealth, privilege, and power.”178 As Francis Fukuyama
states:
What the emergence of a genetic overclass will do to the idea of
universal human dignity is something worth pondering. . . . [T]o
the extent that [bright and successful young people] become
“children of choice” who have been genetically selected by their
parents for certain characteristics, they may come to believe
increasingly that their success is a matter not just of luck but of
good choices and planning on the part of their parents, and hence
something deserved. They will look, think, act, and perhaps even
feel differently from those who were not similarly chosen, and may
come in time to think of themselves to be aristocrats, and unlike
aristocrats of old, their claim to better birth will be rooted in nature
179
and not convention.

However speculative these concerns of inequality may be, they
173.
174.
175.

See id. at 555-56.
See id. at 555.
See JOHN E. J. RASKO, GABRIELLE M. O’ SULLIVAN & RACHEL A. ANKENY, THE
ETHICS OF INHERITABLE GENETIC MODIFICATION: A DIVIDING LINE? 160-61 (2006).
176. See Mehlman, supra note 21, at 533; see also Daniel S. Hamermesh & Jeff E. Biddle,
Beauty and the Labor Market, 84 AM. ECON. REV. 1174, 1192 (1994) (“Other things equal,
wages of people with below-average looks are lower than those of average-looking workers and
there is a premium in wages for good-looking people that is slightly smaller than this penalty.”).
177. See Mehlman, supra note 21, at 577.
178. Id. at 533.
179. FUKUYAMA, supra note 7, at 157.
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must be considered in the context of the future development of RGBs,
and the public policies and regulatory oversight ensuring their safe
and equitable adoption; otherwise opponents’ predictions of genetic
engineering causing irreparable societal dysfunction may become a
reality.

III. POLICY RECOMMENDATIONS
The public policy debate over germline engineering technologies
and HACs raises questions about how these technologies are
regulated now, or should be regulated in the future. This section will
explore the possibilities of regulatory responses to the challenges
posed by new RGBs, from adapting current regulation to the creation
of a new regulatory institution.
A. Current Regulation
1. Federal Regulation of Gene Transfer Research
Presently, there is no federal law or promulgated regulations
directly addressing the genetic modification of gametes or early
embryos, likely because the science supporting genetic modification
is currently unavailable and regarded as purely speculative.180
However, gene transfer research is subject to federal regulations.181
Some commenters believe germline engineering technologies and
HACs could fall under the broad definition of “gene transfer” for
regulatory purposes.182 Thus, this section will examine existing
regulations and discuss whether they apply.
a. NIH and FDA Oversight
There are currently only two principal sources of federal
regulatory oversight of gene-transfer research: the National Institute
of Health (NIH) and the FDA.183 The NIH provides oversight of

180. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 110; but cf. Council of
Europe Convention on Biomedicine and Human Rights, Convention for the Protection of
Human Rights and Dignity of the Human Being with regard to the Application of Biology and
Medicine, Dec. 1, 1999, E.T.S. No. 164 (“An intervention seeking to modify the human genome
may only be undertaken for preventive, diagnostic or therapeutic purposes and only if its aim is
not to introduce any modification in the genome of any descendants.”).
181. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 110-13; see 21 C.F.R. § 1271
(2012).
182. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 110-13.
183. Id.
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gene-transfer technologies and funding applications through the
Recombinant DNA Advisory Committee (RAC) that considers the
social and ethical implications of “novel gene-transfer research
protocols that have some funding connection with NIH.”184 Presently,
the RAC is “responsible for ethical review of all NIH-funded research
proposals that involve putting genes into human beings, [and] is, as a
matter of policy, not reviewing any proposals that seek to modify
gametes or embryos.”185 This decision not to federally fund such
research has created an effective moratorium, except in cases where
the research is privately funded.186
The FDA is tasked with monitoring the safety and effectiveness
of gene-transfer products. The FDA oversees gene-therapy products
that are classified as, “any transfer to a human subject . . . that
introduce[s] genetic material into the body to replace faulty or
missing genetic material (or to alter the regulation of resident genes)
for the treatment or cure of disease . . . .”187 Additionally, the FDA
has asserted authority over gene-therapy products which include
“biologically based articles, such as a subject’s own cells that have
been extracted and modified outside the body prior to re-transfer into
the human subject, or articles (natural or synthetic) that are directly
transferred to the human subject with the intention of genetically
altering his or her cells.”188 The FDA’s claim to authority over genetherapy products came from a published Federal Registrar Notice in
1993,189 which broadly defined its authority and oversight of genetherapy products that, “‘contain genetic materials administered to
modify or manipulate the expression of genetic material or to alter the
biological properties of living cells.’ Such products are subject to the
licensing, false labeling, and misbranding provisions for biologics”190
under the Public Health Service Act (PHSA)191 and drugs under the
U.S. Federal Food, Drug, and Cosmetic Act (FDCA).192 Furthermore,
because the FDA has potentially classified gene-therapy products as

184. Id. at 111.
185. BEYOND THERAPY, supra note 12, at 37-38.
186. See Robertson, supra note 16, at 483; see also FRANKEL & CHAPMAN, supra note 32,
at 8.
187. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 111.
188. Id.
189. See Application of Current Statutory Authorities to Human Somatic Cell Therapy
Products and Gene Therapy Products, 58 Fed. Reg. 53,248, 53,248 (Oct. 14, 1993).
190. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 112.
191. See 42 U.S.C.A. § 262(a) (West 2014).
192. See Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 (2012).
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both biologics and drugs, manufacturers would be required to obtain
both a Biologics License Application (BLA) and a New Drug
Application (NDA).193
However, the FDA’s scope of authority is limited in the respect
that it only has authority to regulate claims of safety and effectiveness
of germline therapy products on human subjects, not the products
themselves. The regulations may not legally apply to early embryos
or gametes that are not considered legal subjects, because human
subject protections only reach embryos once they are implanted
through IVF.194 The Office of Human Research Protections (OHRP)
and the FDA under the Common Rule,195 protect embryos inside a
woman’s uterus as human subjects for purposes of research on
pregnant women and fetuses.196 If the regulations did apply,
presumably the FDA would not approve germline engineering
technologies or HACs, because such technologies have not been
proven safe or effective.197
b. Non-governmental Organization (NGO)
Regulation
Numerous professional societies and NGOs have issued
statements in response to emerging genetic engineering and genetherapy technologies, including American Association for the
Advancement of Sciences (AAAS),198 which “urged an immediate
block on a wide range of clinical procedures that the group labeled
‘inheritable genetic modifications’ (IGM);”199 and the Council for
Responsible Genetics (CRG), which strongly opposes the use of
germline gene modification in humans based on scientific, ethical,
and social concerns.200 Other influential NGOs include the American

193. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 112 (citing Public Health
Service Act 42 U.S.C. § 351(a), 42 U.S.C. § 262(a)).
194. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 111-13.
195. See 45 C.F.R. § 46.201 (2001) (specifically Subpart B--Additional Protections for
Pregnant Women, Human Fetuses and Neonates Involved in Research).
196. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 131-32, 135.
197. See id. at 113.
198. See generally ENITA A. WILLIAMS, GOOD, BETTER, BEST: THE HUMAN QUEST FOR
ENHANCEMENT
(2006)
available
at
http://shr.aaas.org/projects/human_enhance/reports/HESummaryReport.pdf; see also SCOTT F.
GILBERT, DEVELOPMENTAL BIOLOGY (9th ed. 2010) (citing N. Schichor et al., Should We Allow
Genetic Engineering? A Public Policy Analysis of Germline Enhancement, DEVBIO (2010),
http://9e.devbio.com/article.php?id=172.
199. STOCK, supra note 3, at 153; see generally FRANKEL & CHAPMAN, supra note 66.
200. See Council for Responsible Genetics, Position Paper on Human Germline
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Medical Association (AMA), which has stated that “genetic
engineering should be conducted safely, no dangerous viruses should
be employed, and the safety and effectiveness of any such procedures
should be evaluated very closely.”201 Analogous to the CRG’s
response to genetic engineering, the AMA asserts that germline
modification should not be explored because of the “‘welfare of
future generations and its association with risks and potential for
unpredictable and irreversible results.’ Nontherapeutic applications
of gene-transfer are ‘contrary to the ethical traditions of medicine and
against the egalitarian values of society.’”202 While professional
societies do not have formal regulatory authority, their influence on
constituencies and policy makers could have a significant impact on
how current and future genetic engineering legislation is perceived
and directed by the general public.
B. Future Regulation
Once RGBs become feasible, or nearly so, the public may
demand a legislative or regulatory response. This section will
consider four possible policy options.
1. Congress Bans Reproductive Genetic Biotechnologies
(RGBs)
First, those who oppose germline engineering on religious,
moral, or policy grounds might urge Congress to impose a legislative
ban on all pertinent technologies. However, such a ban will likely be
ineffective for several reasons. There are hundreds of fertility clinics
in the United States. These clinics, and the labs associated with them,
offer IVF and related technologies to thousands of clients every day.
Doctors harvest eggs and sperm; labs use those gametes to create
embryos; and doctors then transfer embryos back into the wombs of
women who are anxious to become parents. Throughout all of this
activity, medical privacy reigns supreme. In such a setting, it would
be easy for physicians to employ unauthorized RGB procedures to
alter the gametes or embryos with desired genetic modifications,

Manipulation, COUNCIL FOR RESPONSIBLE GENETICS [hereinafter Human Germline
Manipulation],
available
at
http://www.councilforresponsiblegenetics.org/ViewPage.aspx?pageId=101# (last visited Oct. 2,
2013).
201. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 113; see also Human
Germline Manipulation, supra note 200, at 118.
202. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 111-13.
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under the pretense of a normal IVF procedure.203 As a result, the only
effective way to ban such a practice, would be to ban both therapeutic
and enhancement procedures.204
Moreover, even if RGBs were illegal within the United States,
parents could simply travel to other countries with laxer laws,
undergo IVF with RGBs, and return to the United States to birth the
genetically modified child.205 Such a scenario would likely be too
burdensome for the U.S. to regulate or enforce, because it would
require a controversial determination of whether or not a child has
been illegally enhanced. In addition, law enforcement would need to
establish specific criteria and consequences for illegal “therapy” or
“enhancement,” and under what circumstances children would be
subject to mandatory genetic testing.206 Creating such an elaborate
enforcement scheme would likely prove a complete ban unrealistic,
especially if the enhancement would create a social benefit for both
the individual and society.207
Furthermore, enforcing this Federal-funding ban will likely
prove ineffective, as researchers continue to cross thresholds
previously considered off limits, by replacing human mitochondrial
DNA in embryos to avoid gene mutations that could be epigenetically
passed onto the next generation.208 A similar technique, called
ooplasm transfer209 has produced, to date, thirty children born
worldwide, but it has not been approved for clinical testing within the
United States.210 Therefore, for practical reasons, a future ban on

203. See Mehlman, supra note 21, at 564-65 (“The FDA presently has no authority to
control the prescribing behavior of physicians. Consequently, they are free to prescribe products
for unauthorized uses.”).
204. See id.; see also STOCK, supra note 3, at 153; About Us, EDITAS MEDICINE,
http://editasmedicine.com/about.php (last visited Feb. 25, 2014) (“The company’s mission is to
translate its genome editing technology into a novel class of human therapeutics that enable
precise and corrective molecular modification to treat the underlying cause of a broad range of
diseases at the genetic level.”).
205. But see George J. Annas et al., Protecting the Endangered Human: Toward an
International Treaty Prohibiting Cloning and Inheritable Alterations, 28 AM. J.L. & MED. 151,
154 (2002).
206. See Mehlman, supra note 21, at 565-68.
207. See id. at 565-70.
208. See Masahito Tachibana et al., Towards Germline Gene Therapy of Inherited
Mitochondrial
Diseases,
493
NATURE
627
(2012),
available
at
http://dx.doi.org/10.1038/nature11647.
209. See Kerry L. Macintosh, Brave New Eugenics: Regulating Assisted Reproductive
Technologies in the Name of Better Babies, 2010 U. ILL. J.L. TECH. & POL’Y 257, 271 (2010).
210. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 28, 34; see Jason A.
Barritt et al., Cytoplasmic Transfer in Assisted Reproduction, 7 HUM. REPROD. UPDATE 428,
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RGBs may prove ineffective.
2. Congress Augments the Regulatory Authority of the
FDA
Second, proponents of germline engineering have proposed that
Congress might enact legislation to expand the scope of the FDA’s
authority to cover RGBs. The advantage of this approach is that the
FDA already exists and (arguably) is ready to exercise oversight, at
least on safety and efficacy grounds.211 However, the FDA’s existing
patterns of activity do not regulate RGBs, but rather “drugs, devices,
and biologics that are or will be marketed for use in the United States.
Its principal purpose is to ensure the safety and efficacy of products
according to their approved use.”212 Therefore, in order for the FDA
to expand its jurisdiction to include RGBs, “it might be necessary for
the FDA to construe an embryo that might be transferred into a uterus
as a ‘drug,’ ‘biological product,’ or ‘device.’”213 Classifying future
genetic engineering technologies under the FDA’s definitions of
drugs, biologics, or devices will likely present regulatory challenges,
because each definition carries its own regulatory frameworks that
would require a statutory amendment to define a modified human
embryo as a “product.”214 If Congress fails to ban RGBs, the FDA
will most likely continue to provide regulatory authority over ARTs
and future RGBs, under the auspices of these definitions, as it already
understands the complex challenges involved in exercising
jurisdiction over these broad definitions.215 Furthermore, the FDA’s
unique position distinctively qualifies it to undertake the daunting
responsibility of creating regulatory policies and guidelines that

428-34 (2001).
211. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 188 (The FDA regulates a
broad range of consumer products under the Food, Drug, and Cosmetic Act (FDCA), and the
Public Health Services Act (PHSA)).
212. Id. at 55; see generally Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 301 (West
2014); Public Health Services Act, 42 U.S.C. § 201 (West 2014).
213. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 61.
214. See Elizabeth C. Price, Does the FDA Have Authority to Regulate Human Cloning?,
11 HARV. J. L. & TECH. 619, 638-41 (1998) (arguing the FDA does not have the statutory
authority to regulate embryos as biological products for human cloning).
215. See id. at 55; cf. FRANCIS FUKUYAMA & FRANCO FURGER, BEYOND BIOETHICS: A
PROPOSAL FOR MODERNIZING THE REGULATION OF HUMAN BIOTECHNOLOGIES 231 (2006)
(“Even assuming that by some obscure legal theory the FDA does have the power the adjudicate
contentious ethical questions – i.e., to regulate the use of new reproductive technologies and
biomedical research not exclusively in terms of safety and efficacy – it would be unsuitable for
this task.”).
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would support successful future regulation of RGBs.216
The
following three classifications: (i) drugs, (ii) biologics, and (iii)
devices, are briefly discussed as potential classifications the FDA
could expand to include RGBs within its jurisdiction.
a. Drugs
The FDA could exercise its jurisdiction over RGBs under the
broad statutory definition of “drug” which is defined according to the
Food, Drug, and Cosmetic Act (FDCA), as “encompassing any
officially recognized article that is either (1) intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease in
man, or (2) (excepting foods) intended to affect the structure or any
function of the body of man.”217 The definition of a drug or dietary
supplement under the FDA currently categorizes pharmaceutical
products, or off-label products, which are subject to premarket
authorization.
However, classifying RGBs as drugs likely
encompasses too broad of a definition and offers inadequate
regulation for a drug that would change the structure and function of
the human body.218
b. Biological Products
The FDA under the PHSA has the regulatory authority to
regulate “biological products,” defined as “‘any virus, therapeutic
serum, toxin, anti-toxin, vaccine, blood, blood component or
derivative, allergenic product or analogous product, applicable to the
prevention, treatment or cure of diseases or injuries to humans.’”219
Similarly, an Investigational New Drug Application (IND) required
for drugs, and biologics must also undergo an approval process
through a Biologics License Application (BLA), which requires the
product be “safe, pure, and potent.”220 In addition, under the FDA’s
authority to regulate biological products, it oversees the Center for
Biologics Evaluation and Research (CBER), which has “undertaken

216. See Christine Willgoos, FDA Regulation: An Answer to the Questions of Human
Cloning and Germline Gene Therapy, 27 AM. J.L. & MED. 101, 119-24 (2001) (“[T]he FDA
appears to be a good candidate for the oversight of genetically manipulated reproductive
technology.”).
217. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 55-56.
218. See JULIAN SAVULESCU ET AL., supra note 11, at 511.
219. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 56 (citing 42 U.S.C. § 262(i)
(West 2014)).
220. Id. at 57.
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regulation of cellular and gene-therapy products,” 221 which must
meet the same pre-market standards for safety as drugs. Therefore,
the FDA could potentially encompass future gene-modification RGB
products under a strained biologic definition, but such a classification
for enhancement may not be suitable.
c. Devices
According to the FDA, the products that are subject to premarket
authorization include drugs, biological products, food additives, and
devices that the FDA reviews on a product-by-product basis, and
“determines whether the proposed device is substantially equivalent
to a product that is already on the market.”222 Similar to the definition
of “drug” and “biological product” discussed earlier, a “device” is
defined as any “‘instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar related article,
including any component’ that is officially recognized, intended for
the diagnosis, treatment, cure, mitigation, or prevention of disease in
man, or intended to affect the structure and function of the body.”223
The FDA reviewers often require manufactures to provide product
related scientific research data and detailed product information when
submitting a product to the FDA in order to support their regulatory
decisions—those presenting greater safety risks such as RGBs would
likely be subject to a more rigorous pre-market approval process for
safety and effectiveness.224 However, because the FDA’s regulatory
authority only regulates products and claims about products, not the
technologies themselves; the FDA may not be aware of the
unsanctioned use of RGBs on the market, a safety problem perceived
by many as a serious regulatory inadequacy.225 However, looking at
how medical devices are currently regulated and examining their
efficacy under the FDA’s FDCA may help illustrate the FDA’s ability
to adequately regulate RGBs as medical devices, rather than drugs, or
biologics now and in the future. Devices are regulated in a tiered
three level classification system that is based on the relative degree of
risk associated with the product:226 Class I or II devices are
221. Id.
222. Id. at 59.
223. Id. at 58.
224. Id. at 59.
225. See Robertson, supra note 16, at 483; see also Mehlman, supra note 21, at 564-66
(suggesting the DEA rather then the FDA may be the most appropriate government agency to
regulate genetic enhancements).
226. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 59.
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considered low risk in which the safety and effectiveness are well
established; Class III devices are the most complex and significantly
high-risk devices used to sustain or support life, or those implanted in
the human body.227 Therefore, although the FDA’s definition of
devices could likely incorporate future RGBs as Class III devices,
Congress would be required to augment the FDA’s regulatory
authority beyond its current classification system to adequately
consider the moral concerns of RGBs.
3. Congress Creates a New Independent Regulatory
Agency
Third, Congress could enact legislation authorizing the creation
of a new regulatory agency focused specifically on the oversight of
genetic engineering biotechnologies. This ambitious task would
require the new agency to be more competent than the FDA to deal
with the complex array of social, ethical, and legal issues. In practice,
this new independent agency could more effectively decrease
bureaucracy currently existing between multiple agencies claiming
authority, and provide unified regulatory guidance for research and
development funding requirements.228 Traditionally Congress has
established independent regulatory agencies to oversee specific
policy-making areas that require extensive expertise and judgment,
and provide isolation from political considerations.229 Currently,
many of the emerging issues discussed in assisted reproduction,
genetic engineering, and RGBs are new and unprecedented, and do
not fall naturally into the jurisdiction of any existing government
body or agency.230 This new agency could be authorized to directly
consider policy concerns that extend beyond the FDA’s purview of
safety and efficacy.
Initially, a new agency tasked with regulatory authority over
genetic engineering technologies, would need to be cautious not to
expand its authority to include differentiating biotechnologies as
either therapy or enhancement.
Granting such authority to
differentiate between the approval of technologies for therapy and not
enhancement purposes, could grant this new governmental regulatory
agency an effective monopoly over which future biological traits of
its citizens are acceptable; a fear shared by many opponents of IGM
227.
228.
229.
230.

See id.
See FUKUYAMA, supra note 7, at 215.
See FUKUYAMA & FURGER, supra note 215, at 293-311.
See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 187.
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as a method of eugenics.231 Opponents such as Fukuyama argue that
the “FDA [or a new agency] is not set up to make politically sensitive
decisions concerning the point at which selection for characteristics
like intelligence and height ceases to be therapeutic and becomes
enhancing, or whether these characteristics can be considered
therapeutic at all.”232
Other nations have already created independent agencies to
address these challenges such as: the Human Fertilization and
Embryology Authority (HFEA) in Britain, and the Assisted Human
Reproduction Agency (AHRA) in Canada.233 In response, some
commenters have suggested that the creation of a new regulatory
agency would likely resemble Britain’s HFEA,234 and would act with
its new federal authority to place greater restrictions on RGBs.235
However, a new regulatory agency could potentially accelerate future
research and development of RGBs, if national attention and focus is
brought to the issue through a national conversation that has
previously remained largely inaccessible to the general public.236
Furthermore, creation of an independent agency may be more adept at
handling the complex policies required of RGBs, but it could
arguably lead to more restrictive regulation if political conflicts over
embryo status, federal research funding, and abortion rights shift the
focus of its purpose.237 As several commenters have suggested, if left
to free-market forces, “[m]ost regulation will occur informally
through the market interactions of willing consumers and providers of
these services against a background of common law norms, some
professional self-regulation, and occasional state legislative
intrusions.”238 Therefore, Congress could decide to give the FDA the
power to consider moral and philosophical issues of RGBs, thereby

231.
232.
233.

See Mehlman, supra note 21, at 556-57.
FUKUYAMA, supra note 7, at 213.
See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 187; FUKUYAMA &
FURGER, supra note 215, at 149-79.
234. See Letter from the Center for Genetics and Society addressing HFEA’s current
consultation on Mitochondrial Replacement Research (Nov. 15, 2012) (The HFEA launched a
public consultation to gather views on the social and ethical impact of mitochondria replacement
techniques. In response the CRG sent a letter to the HFEA, strongly recommending that the
current UK law prohibiting germline engineering remain in effect), available at
http://www.biopoliticaltimes.org/downloads/Letter%20to%20HFEA.pdf.
235. See Robertson, supra note 16, at 482-84; see also REPRODUCTION AND
RESPONSIBILITY, supra note 5, at 187.
236. See generally FRANKEL & CHAPMAN, supra note 68.
237. See Robertson, supra note 16, at 482; see also, Macintosh, supra note 209, at 292-93.
238. See Robertson, supra note 16, at 483-84.
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expanding its regulatory authority without having to distort its current
three-tier classifications. However, such a radical change would
require reorganization of the agency and its staffers to address the
emerging social, ethical, and philosophical issues of RGBs. If those
elements were to be considered by the FDA, it would make more
sense for Congress to focus its resources on creating a new
independent agency and framework for oversight with new staffers
that have the relevant expertise.239 This new agency should be tasked
with promoting a national conversation about the acceptable uses of
RGBs for therapeutic and enhancement applications, designing
mechanisms for assessing the social, ethical, and safety risks
involved, encouraging the creation of public and private policy
guidelines, and serving as a single data repository and funding
recommendation mechanism for genetic research on animals and
humans.240 An agency tasked with these responsibilities and
regulatory authority would be able to adequately perform independent
scientific and ethical reviews of all RGB research protocols and
procedures.241
CONCLUSION
As the biotechnology revolution increases humankind’s genomic
knowledge, our current abilities using ARTs, and the future
possibilities of RGBs, the bioethical, legal, and social challenges of
choosing our children’s genes will require comprehensive policy
frameworks and regulatory oversight of these technologies to ensure
their safe and effective development. Public awareness and attitudes
of genetic engineering will influence its evolution, and public policy
needs to adapt with unique regulations that consider the greater social
and moral implications. Scientific advancements may provide the
opportunity to fundamentally alter our evolution and biological
potential as a species by rejecting the archaic practice of random
genetic variation through sexual reproduction and natural selection.
However, before we adopt RGBs that go beyond therapy for
enhancement of our bodies and our minds, we must promote equality
and fairness; otherwise we risk potential social and economic

239. See FRANKEL & CHAPMAN, supra note 32, at 51.
240. See id. at 51-53.
241. See id.; FUKUYAMA & FURGER, supra note 215, at 297-98 (“This organizational form
is a far better match for what may be described as the two main tasks facing a regulatory agency
responsible for overseeing reproductive medicine and biomedical research – implementing the
Congressional mandate and adjudicating societal disputes – than an executive agency.”).
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instability where genetic discrimination fragments society into a
genetic aristocracy. Rather than continuing to place federal-funding
restrictions on technological advances in genetic engineering,
policymakers need to recognize such economic mechanisms or
temporary bans will likely prove ineffective, and need to be
reconsidered. One such proposed solution for policymakers is the
creation of a new independent regulatory agency tasked specifically
to address these issues, rather than attempting to augment the FDA’s
existing policy framework and statutory definitions to meet the needs
of these emerging challenges. The creation of a new regulatory
agency would appropriately balance arguments advanced by both
proponents and opponents of genetic engineering technologies used in
assisted reproduction. Its creation would support the responsible and
safe adoption of RGBs to increase human prosperity, while
simultaneously providing adequate regulatory oversight, and
enforcement mechanisms if parents one day decide to choose the
genetics of their children.

